Identification of novel and available Bacillus anthracis inhibitors using drug repurposing approach and in-silico methods
by Masood Aleeyar; Hamid Moghimi; Abbas Abbas Rouhollahi; Ramezan Ali Taheri
International Journal of Bioinformatics Research and Applications (IJBRA), Vol. 17, No. 6, 2021

Abstract: Anthrax is a dangerous disease all around the world and it can be lethal if it is not properly treated. In order to address this problem, we decided to use the combination of drug repurposing and structure-based drug discovery to identify useful and effective alternative treatment for the anthrax. In this study, we used molecular docking, molecular dynamics simulations and related analysis and found that Kanamycin, Tobramycin and Framycetin can be potential drugs for the treatment of anthrax. Moreover, because our identified compounds are FDA approved drugs, there is no need to pass any safety test and all of the hit compounds can be tested in real people.

Online publication date: Tue, 25-Jan-2022

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Bioinformatics Research and Applications (IJBRA):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com